These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28643528)

  • 1. Modulating release of ranibizumab and aflibercept from thiolated chitosan-based hydrogels for potential treatment of ocular neovascularization.
    Moreno M; Pow PY; Tabitha TST; Nirmal S; Larsson A; Radhakrishnan K; Nirmal J; Quah ST; Geifman Shochat S; Agrawal R; Venkatraman S
    Expert Opin Drug Deliv; 2017 Aug; 14(8):913-925. PubMed ID: 28643528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of stability and biophysical characterization of ranibizumab and aflibercept.
    Moreno MR; Tabitha TS; Nirmal J; Radhakrishnan K; Yee CH; Lim S; Venkatraman S; Agrawal R
    Eur J Pharm Biopharm; 2016 Nov; 108():156-167. PubMed ID: 27615995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled and Extended In Vitro Release of Bioactive Anti-Vascular Endothelial Growth Factors from a Microsphere-Hydrogel Drug Delivery System.
    Osswald CR; Kang-Mieler JJ
    Curr Eye Res; 2016 Sep; 41(9):1216-22. PubMed ID: 26764892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
    Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
    Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro.
    Liu W; Lee BS; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2019 Mar; 44(3):264-274. PubMed ID: 30295090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
    Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
    Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing.
    Szabo SM; Hedegaard M; Chan K; Thorlund K; Christensen R; Vorum H; Jansen JP
    Curr Med Res Opin; 2015 Nov; 31(11):2031-42. PubMed ID: 26296050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S; Muether PS
    Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells.
    Arnott C; Punnia-Moorthy G; Tan J; Sadeghipour S; Bursill C; Patel S
    PLoS One; 2016; 11(3):e0150688. PubMed ID: 26959822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System.
    Osswald CR; Guthrie MJ; Avila A; Valio JA; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2017 Sep; 42(9):1293-1301. PubMed ID: 28557571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Timing of the First Recurrence in Neovascular Age-Related Macular Degeneration: Comparison Between Ranibizumab and Aflibercept.
    Kim JH; Chang YS; Lee DW; Kim CG; Kim JW
    J Ocul Pharmacol Ther; 2017; 33(6):445-451. PubMed ID: 28384009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term in vitro functional stability of compounded ranibizumab and aflibercept.
    Cao S; Cui J; Matsubara J; Forooghian F
    Can J Ophthalmol; 2017 Jun; 52(3):273-276. PubMed ID: 28576208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.
    Maksys S; Richter-Müksch S; Weingessel B; Vécsei-Marlovits PV
    Wien Klin Wochenschr; 2017 May; 129(9-10):351-357. PubMed ID: 27550436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration].
    Ziegler M; Heimes B; Book B; Dietzel M; Zeimer M; Spital G; Gutfleisch M; Pauleikhoff D; Lommatzsch A
    Ophthalmologe; 2015 May; 112(5):435-43. PubMed ID: 25523611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.